Peskov After Turkey's Refusal to Buy Sputnik V: Trials Showed Vaccine's Effectiveness
15:25 GMT 09.12.2020(updated 18:14 GMT 09.12.2020)
MOSCOW, (Sputnik) - The results of trials of the Russian vaccine against coronavirus Sputnik V indicate its effectiveness and reliability, it can and will certainly play an important role in the fight against the pandemic, Kremlin spokesman Dmitry Peskov told Sputnik amid Turkey's refusal to purchase Sputnik V.
"We can say unequivocally â€” the results of testing and trials indicate that this is a very effective and reliable vaccine, which can and will certainly play a very important role in the fight against the pandemic," Peskov said, answering whether the Russian vaccine met all standards and whether there were any questions about its effectiveness.
Earlier in the day, the Haberturk broadcaster reported, citing Turkish Health Minister Fahrettin Koca, that Ankara would not purchase Russian vaccine against coronavirus, as it allegedly did not comply with good laboratory practice.
Turkish Health Minister, however, has not confirmed the rejection of Russian vaccine against COVID-19.
"As for the Russian vaccine. As you know, it must undergo proper laboratory practice in toxicology. We are starting this work in our country. If everything is successful, I can say that there will be no problems," he told reporters.
A source in the Russian Direct Investment Fund meanwhile told Sputnik on Wednesday, that Russia and Turkey were still discussing Sputnik V.
Russia registered the world's first coronavirus vaccine, Sputnik V, on 11 August. About 50 countries have already ordered 1.2 billion doses of the vaccine. Sputnik V is a two-component treatment based on adenoviral vector, which, according to scientists, normally causes acute respiratory viral infections and makes people develop immunity to the virus for at least two years. The vaccine was developed jointly by the Gamaleya Research Institute, the Russian Defence Ministry, and is being distributed by the Russian Direct Investment Fund (RDIF).
|Join the GlobalSecurity.org mailing list|